VoigtLF, WeissNS, ChuJ. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet1991; 338: 274–7.
2.
WeiderpassE, AdamiHO, BaronJA. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst1999; 91: 1131–7.
3.
SturdeeDW, UlrichLG, BarlowDH. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG2000; 107: 1392–400.
4.
AndersonGL, JuddHL, KaunitzAM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA2003; 290: 1739–48.
5.
Schering Health Care.Mirena Summary of Product Characteristics. September 2004
6.
ZhuP, LiuX, LuoH. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Hum Reprod1999; 14: 970–5.
7.
VarilaE, WahlströmT, RauramoI. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril2001; 76: 969–73.
8.
RiphagenFE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric2000; 3: 199–211.
9.
RaudaskoskiT, TapanainenJ, TomásE. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG2002; 109: 136–44.
10.
RaudaskoskiTH, LahtiEI, KauppilaAJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol1995; 172: 114–19.
11.
BackmanT, RauramoI, JaakkolaK. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol2005; 106: 813–17.
